Melanoma Resistant to Anti-PD-1 Responds to Tumor Infiltrating Lymphocytes

(MedPage Today) -- Almost a third of post-immunotherapy melanomas responded to cellular therapy with tumor-infiltrating lymphocytes (TILs), data from a multicohort study showed. Overall, 31.4% of 153 patients responded to lifileucel TILs (LN-144...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news